In Brief: Biological Response Modifiers Advisory Committee

Biological Response Modifiers Advisory Committee: Will discuss CellPro's PMA 94-001 for its Ceprate SC device for selection of CD34+ progenitor/stem cells on Feb. 28, followed by an update on stem cell policy. On Feb. 29, the committee will consider issues in early clinical trial development of in utero stem cell transplantation and the draft document "Addendum on gene therapy to the 1991 points-to-consider on human somatic cell and gene therapy." The meeting will begin at 8:30 a.m. at the Bethesda, Md. Holiday Inn...